Technical Analysis for MRNS - Marinus Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Flat |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
20 DMA Resistance | Bearish | -3.94% | |
20 DMA Resistance | Bearish | 0.78% | |
20 DMA Resistance | Bearish | -4.45% | |
Shooting Star Candlestick | Bearish | -4.45% | |
Calm After Storm | Range Contraction | -4.45% | |
NR7 | Range Contraction | -4.45% | |
Lower Bollinger Band Walk | Weakness | -4.45% | |
Crossed Above 200 DMA | Bullish | -2.80% |
Alert | Time |
---|---|
10 DMA Support | about 19 hours ago |
Outside Day | about 20 hours ago |
Down 5% | about 20 hours ago |
Down 3% | about 20 hours ago |
Fell Below Previous Day's Low | about 20 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/05/2024
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing neuropsychiatric therapeutics. It offers Ganaxolone, a synthetic small molecule, which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures; and is in proof-of-concept Phase II clinical trial as a treatment for behaviors in the orphan indication Fragile X Syndrome in children. The company has a collaboration agreement with NovaMedica, LLC, as well as a license agreement with Purdue Neuroscience Company. Marinus Pharmaceuticals, Inc. was founded in 2003 and is headquartered in New Haven, Connecticut.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Ketones Seizure Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Alcohol Neuroscience Ketones Seizure Sedatives Fragile X Syndrome Pregnanes Neurosteroids
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.26 |
52 Week Low | 5.5704 |
Average Volume | 420,032 |
200-Day Moving Average | 8.60 |
50-Day Moving Average | 9.80 |
20-Day Moving Average | 9.40 |
10-Day Moving Average | 9.04 |
Average True Range | 0.62 |
RSI (14) | 44.44 |
ADX | 27.66 |
+DI | 15.06 |
-DI | 26.12 |
Chandelier Exit (Long, 3 ATRs) | 8.65 |
Chandelier Exit (Short, 3 ATRs) | 10.00 |
Upper Bollinger Bands | 10.25 |
Lower Bollinger Band | 8.54 |
Percent B (%b) | 0.28 |
BandWidth | 18.17 |
MACD Line | -0.20 |
MACD Signal Line | -0.19 |
MACD Histogram | -0.0128 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 10.30 | ||||
Resistance 3 (R3) | 10.38 | 10.03 | 10.08 | ||
Resistance 2 (R2) | 10.03 | 9.71 | 9.99 | 10.01 | |
Resistance 1 (R1) | 9.53 | 9.51 | 9.36 | 9.45 | 9.94 |
Pivot Point | 9.18 | 9.18 | 9.10 | 9.14 | 9.18 |
Support 1 (S1) | 8.68 | 8.86 | 8.51 | 8.60 | 8.10 |
Support 2 (S2) | 8.33 | 8.66 | 8.29 | 8.03 | |
Support 3 (S3) | 7.83 | 8.33 | 7.96 | ||
Support 4 (S4) | 7.75 |